BR112015005743A2 - derivados tricíclicos de quinoxalina e quinolina - Google Patents
derivados tricíclicos de quinoxalina e quinolinaInfo
- Publication number
- BR112015005743A2 BR112015005743A2 BR112015005743A BR112015005743A BR112015005743A2 BR 112015005743 A2 BR112015005743 A2 BR 112015005743A2 BR 112015005743 A BR112015005743 A BR 112015005743A BR 112015005743 A BR112015005743 A BR 112015005743A BR 112015005743 A2 BR112015005743 A2 BR 112015005743A2
- Authority
- BR
- Brazil
- Prior art keywords
- tricyclic
- quinoxaline
- quinoline derivatives
- ht2c receptor
- quinoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
resumo derivados tricíclicos de quinoxalina e quinolina a presente invenção refere-se aos derivados tricíclicos de quinolina e quinoxalina, a uma composição farmacêutica contendo esses compostos, aos seus usos como moduladores, especialmente agonistas ou agonistas parciais do receptor 5-ht2c, ao uso na preparaçao de um medicamento para prevenir ou tratar as condições e doenças que respondem à modulação do receptor 5-ht2c, e a um método para prevenir ou tratar as condições e doenças que respondem à modulação do receptor 5-ht2c.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261701531P | 2012-09-14 | 2012-09-14 | |
| US201261701514P | 2012-09-14 | 2012-09-14 | |
| US201361793033P | 2013-03-15 | 2013-03-15 | |
| CN201310410951.1A CN104418862A (zh) | 2013-09-11 | 2013-09-11 | 三环喹啉和喹喔啉衍生物 |
| PCT/EP2013/069036 WO2014041131A1 (en) | 2012-09-14 | 2013-09-13 | Tricyclic quinoline and quinoxaline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015005743A2 true BR112015005743A2 (pt) | 2017-07-04 |
Family
ID=50275085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015005743A BR112015005743A2 (pt) | 2012-09-14 | 2013-09-13 | derivados tricíclicos de quinoxalina e quinolina |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10118926B2 (pt) |
| EP (1) | EP2895485A1 (pt) |
| JP (1) | JP6290217B2 (pt) |
| KR (1) | KR20150056608A (pt) |
| CN (1) | CN104995191A (pt) |
| AR (1) | AR092568A1 (pt) |
| AU (2) | AU2013314279B2 (pt) |
| BR (1) | BR112015005743A2 (pt) |
| CA (1) | CA2884548A1 (pt) |
| CL (1) | CL2015000628A1 (pt) |
| CR (1) | CR20150186A (pt) |
| DO (1) | DOP2015000058A (pt) |
| EC (1) | ECSP15012766A (pt) |
| HK (1) | HK1212684A1 (pt) |
| IL (1) | IL237726A0 (pt) |
| IN (1) | IN2015DN02070A (pt) |
| MX (1) | MX2015003364A (pt) |
| NZ (1) | NZ631187A (pt) |
| PE (1) | PE20150777A1 (pt) |
| PH (1) | PH12015500551A1 (pt) |
| RU (1) | RU2015113558A (pt) |
| SG (1) | SG11201501894VA (pt) |
| TW (1) | TW201414735A (pt) |
| UA (1) | UA116216C2 (pt) |
| UY (1) | UY35029A (pt) |
| WO (1) | WO2014041131A1 (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| JP6554037B2 (ja) | 2013-01-15 | 2019-07-31 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用なチアゾールカルボキサミドおよびピリジンカルボキサミド化合物 |
| DK2968320T3 (da) | 2013-03-15 | 2021-02-01 | Intra Cellular Therapies Inc | Organiske forbindelser |
| AU2014308703A1 (en) | 2013-08-23 | 2016-03-24 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as Pim kinase inhibitors |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| JP6475727B2 (ja) | 2013-12-03 | 2019-02-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規方法 |
| US9573950B2 (en) | 2014-03-14 | 2017-02-21 | Abbvie Deutschland Gmbh & Co Kg | Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators |
| EP3116874B1 (en) | 2014-03-14 | 2018-02-28 | AbbVie Deutschland GmbH & Co. KG | Hexahydrodiazepinoquinolines carrying a substituted alkyl radical |
| BR112016023162B1 (pt) | 2014-04-04 | 2022-11-29 | Intra-Cellular Therapies, Inc | Compostos orgânicos gama-carbolinas, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento ou na profilaxia de transtornos de sistema nervoso central |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
| WO2017117514A1 (en) * | 2015-12-31 | 2017-07-06 | Tung Roger D | Deuterated iti-007 |
| RU2743513C2 (ru) | 2016-01-26 | 2021-02-19 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| WO2017165755A1 (en) * | 2016-03-25 | 2017-09-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| PL3407889T3 (pl) | 2016-03-25 | 2021-11-22 | Intra-Cellular Therapies, Inc. | Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| EP3525763A4 (en) | 2016-10-12 | 2020-06-17 | Intra-Cellular Therapies, Inc. | AMORPHE FIXED DISPERSIONS |
| US10906906B2 (en) | 2016-12-29 | 2021-02-02 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| US20210009592A1 (en) * | 2018-03-23 | 2021-01-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2023068755A1 (ko) * | 2021-10-18 | 2023-04-27 | 주식회사 사피엔스바이오 | 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| KR102600176B1 (ko) * | 2021-10-18 | 2023-11-10 | 주식회사 사피엔스바이오 | 신규한 화합물 및 이를 포함하는 약학적 조성물 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3714149A (en) | 1969-11-03 | 1973-01-30 | Upjohn Co | Pyridobenzodiazepinones |
| JP2955358B2 (ja) | 1989-06-09 | 1999-10-04 | ファルマシア・アンド・アップジョン・カンパニー | 中枢神経系活性を有する複素環系アミン |
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| US6277985B1 (en) | 1995-09-15 | 2001-08-21 | Pharmacia & Upjohn Company | Aminoaryl oxazolidinone N-oxides |
| ZA9711274B (en) * | 1996-12-16 | 1998-06-23 | Warner Lambert Co | Tricyclic quinoxaline derivatives as neuroprotective agents. |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| AU2002227170A1 (en) * | 2000-11-03 | 2002-05-15 | Wyeth | Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives |
| TWI312781B (en) * | 2002-04-25 | 2009-08-01 | [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | |
| TW200307682A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| US20080146583A1 (en) | 2003-05-15 | 2008-06-19 | Pfizer Inc | Treatment of Incontinence |
| US7307163B2 (en) | 2004-04-19 | 2007-12-11 | Symed Labs Limited | Process for the preparation of linezolid and related compounds |
| EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| WO2007112073A2 (en) | 2006-03-24 | 2007-10-04 | Wyeth | Methods for modulating bladder function |
| CA2644662A1 (en) | 2006-03-24 | 2007-10-04 | Wyeth | New therapeutic combinations for the treatment of depression |
| WO2007112000A2 (en) * | 2006-03-24 | 2007-10-04 | Wyeth | Treatment of pain |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| KR101222412B1 (ko) | 2007-02-15 | 2013-01-15 | 에프. 호프만-라 로슈 아게 | Ｔａａｒ1 리간드로서의 2-아미노옥사졸린 |
| KR20100012031A (ko) | 2007-04-19 | 2010-02-04 | 콘서트 파마슈티컬즈, 인크. | 중수소화된 모르폴리닐 화합물 |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| WO2009045476A1 (en) | 2007-10-02 | 2009-04-09 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| CA2703591C (en) | 2007-10-26 | 2013-05-07 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| EP2522671B1 (en) * | 2009-04-23 | 2016-01-20 | AbbVie Inc. | Modulators of 5-HT receptors and methods of use thereof |
| US20140080813A1 (en) * | 2012-09-14 | 2014-03-20 | AbbVie Deutschland GmbH & Co. KG | Tricyclic quinoline and quinoxaline derivatives |
-
2013
- 2013-09-13 NZ NZ631187A patent/NZ631187A/en not_active IP Right Cessation
- 2013-09-13 UA UAA201503409A patent/UA116216C2/uk unknown
- 2013-09-13 AR ARP130103294A patent/AR092568A1/es unknown
- 2013-09-13 US US14/026,354 patent/US10118926B2/en active Active
- 2013-09-13 SG SG11201501894VA patent/SG11201501894VA/en unknown
- 2013-09-13 CN CN201380059579.2A patent/CN104995191A/zh active Pending
- 2013-09-13 BR BR112015005743A patent/BR112015005743A2/pt not_active IP Right Cessation
- 2013-09-13 PE PE2015000363A patent/PE20150777A1/es not_active Application Discontinuation
- 2013-09-13 IN IN2070DEN2015 patent/IN2015DN02070A/en unknown
- 2013-09-13 WO PCT/EP2013/069036 patent/WO2014041131A1/en active Application Filing
- 2013-09-13 UY UY0001035029A patent/UY35029A/es not_active Application Discontinuation
- 2013-09-13 MX MX2015003364A patent/MX2015003364A/es unknown
- 2013-09-13 EP EP13762483.9A patent/EP2895485A1/en not_active Withdrawn
- 2013-09-13 CA CA2884548A patent/CA2884548A1/en not_active Abandoned
- 2013-09-13 AU AU2013314279A patent/AU2013314279B2/en not_active Ceased
- 2013-09-13 RU RU2015113558A patent/RU2015113558A/ru not_active Application Discontinuation
- 2013-09-13 KR KR1020157009502A patent/KR20150056608A/ko not_active Application Discontinuation
- 2013-09-13 JP JP2015531577A patent/JP6290217B2/ja not_active Expired - Fee Related
- 2013-09-14 TW TW102133403A patent/TW201414735A/zh unknown
-
2015
- 2015-03-12 IL IL237726A patent/IL237726A0/en unknown
- 2015-03-13 PH PH12015500551A patent/PH12015500551A1/en unknown
- 2015-03-13 DO DO2015000058A patent/DOP2015000058A/es unknown
- 2015-03-13 CL CL2015000628A patent/CL2015000628A1/es unknown
- 2015-04-01 EC ECIEPI201512766A patent/ECSP15012766A/es unknown
- 2015-04-10 CR CR20150186A patent/CR20150186A/es unknown
-
2016
- 2016-01-18 HK HK16100520.1A patent/HK1212684A1/zh unknown
-
2018
- 2018-01-24 AU AU2018200572A patent/AU2018200572A1/en not_active Abandoned
- 2018-11-02 US US16/179,050 patent/US20190071443A1/en not_active Abandoned
-
2019
- 2019-10-14 US US16/601,075 patent/US20200283439A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140080816A1 (en) | 2014-03-20 |
| IN2015DN02070A (pt) | 2015-08-14 |
| PH12015500551A1 (en) | 2015-05-04 |
| US10118926B2 (en) | 2018-11-06 |
| UY35029A (es) | 2014-04-30 |
| AR092568A1 (es) | 2015-04-22 |
| EP2895485A1 (en) | 2015-07-22 |
| KR20150056608A (ko) | 2015-05-26 |
| AU2013314279B2 (en) | 2017-11-02 |
| IL237726A0 (en) | 2015-05-31 |
| JP6290217B2 (ja) | 2018-03-07 |
| US20190071443A1 (en) | 2019-03-07 |
| CN104995191A (zh) | 2015-10-21 |
| AU2018200572A1 (en) | 2018-02-15 |
| NZ631187A (en) | 2017-03-31 |
| CA2884548A1 (en) | 2014-03-20 |
| ECSP15012766A (es) | 2017-06-30 |
| UA116216C2 (uk) | 2018-02-26 |
| PE20150777A1 (es) | 2015-06-20 |
| DOP2015000058A (es) | 2015-04-15 |
| CL2015000628A1 (es) | 2015-10-30 |
| SG11201501894VA (en) | 2015-04-29 |
| MX2015003364A (es) | 2016-03-31 |
| WO2014041131A1 (en) | 2014-03-20 |
| AU2013314279A1 (en) | 2015-04-02 |
| RU2015113558A (ru) | 2016-11-10 |
| US20200283439A1 (en) | 2020-09-10 |
| JP2015528478A (ja) | 2015-09-28 |
| HK1212684A1 (zh) | 2016-06-17 |
| TW201414735A (zh) | 2014-04-16 |
| CR20150186A (es) | 2015-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015005743A2 (pt) | derivados tricíclicos de quinoxalina e quinolina | |
| NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
| BR112017003346B8 (pt) | Derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
| BR112015022417A2 (pt) | métodos e composições para inibição de proteínas contendo bromodomínio | |
| BR112017002221A2 (pt) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| DOP2013000192A (es) | Compuestos y composiciones como inhibidores de la trk | |
| BR112015008480A2 (pt) | compostos de benzeno substituído | |
| UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
| BR112015023142A8 (pt) | moduladores do p2x7,seu uso, processo de preparação e composição farmacêutico que os compreende | |
| UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
| BR112015029090A8 (pt) | 3,4-dihidroisoquinolin- 2(1h)-ila, seus usos, composição farmacêuticas e sua forma cocristalina | |
| CO7111276A2 (es) | Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met | |
| BR112017010311A2 (pt) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| BR112016011170A8 (pt) | derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica | |
| BR112016022593A2 (pt) | composições e métodos para modular a expressão do fator b do complemento | |
| BR112014022214A2 (pt) | fenólicos antibacterianos | |
| NI201500096A (es) | Compuesto químicos | |
| BR112016024421A2 (pt) | composição farmacêutica, cápsula e uso da composição farmacêutica | |
| ECSP15000868A (es) | Derivados de estra1,3,5(10),16tetraeno 3sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| CR20130056A (es) | Derivados heterocíclicos fusionados como moduladores s1p | |
| CL2015001187A1 (es) | Compuestos derivados de azaquinolin-carboxamida, como inhibidores de p70s6k; su metodo de manufactura; composicion farmaceutica que los comprende; y su uso para el tratamiento profilactico o terapeutico de trastornos hiperproliferativos, cancer, retinopatia diabetica, dolor, eczema y degeneracion macular relacionada con la edad, entre otras enfermedades. | |
| BR112016000338A8 (pt) | composto enriquecido em deutério de fórmula estrutural i, composição farmacêutica, e usos de um composto | |
| BR112015000616A2 (pt) | tratamento da esclerose múltipla com combinação de laquinimode e fampridina | |
| BR112014029280A2 (pt) | novos compostos | |
| CL2016001024A1 (es) | Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2531 DE 09-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |